Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Hematopoietic stem cell based gene therapy for HIV diseases
Advertisements

by Jad I. Belle, David Langlais, Jessica C
Combined Effects of Interleukin-7 and Stem Cell Factor Administration on Lymphopoiesis after Murine Bone Marrow Transplantation  Brile Chung, Dullei Min,
Volume 45, Issue 5, Pages (November 2016)
Volume 25, Issue 10, Pages (October 2017)
Molecular Therapy - Nucleic Acids
Volume 136, Issue 4, Pages e3 (April 2009)
Local Inflammatory Cues Regulate Differentiation and Persistence of CD8+ Tissue- Resident Memory T Cells  Tessa Bergsbaken, Michael J. Bevan, Pamela J.
Human NK cell development in NOD/SCID mice receiving grafts of cord blood CD34+ cells by Christian P. Kalberer, Uwe Siegler, and Aleksandra Wodnar-Filipowicz.
Volume 25, Issue 9, Pages (September 2017)
by Silke Huber, Reinhard Hoffmann, Femke Muskens, and David Voehringer
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
Ubiquitous high-level gene expression in hematopoietic lineages provides effective lentiviral gene therapy of murine Wiskott-Aldrich syndrome by Alexander.
Molecular Therapy - Methods & Clinical Development
Altered Homeostasis of CD4+ Memory T Cells in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Chronic Graft-versus-Host Disease Enhances T Cell.
Volume 20, Issue 7, Pages (July 2012)
Volume 13, Issue 6, Pages (November 2015)
miR-150-Mediated Foxo1 Regulation Programs CD8+ T Cell Differentiation
Volume 42, Issue 5, Pages (May 2015)
David Voehringer, Kanade Shinkai, Richard M Locksley  Immunity 
Volume 21, Issue 5, Pages (October 2017)
Volume 45, Issue 2, Pages (August 2016)
Volume 14, Issue 12, Pages (March 2016)
Viral Infection Results in Massive CD8+ T Cell Expansion and Mortality in Vaccinated Perforin-Deficient Mice  Vladimir P Badovinac, Sara E Hamilton, John.
Volume 3, Issue 5, Pages (November 2014)
Volume 4, Issue 4, Pages (October 2008)
Combined Effects of Interleukin-7 and Stem Cell Factor Administration on Lymphopoiesis after Murine Bone Marrow Transplantation  Brile Chung, Dullei Min,
Volume 140, Issue 4, Pages (April 2011)
Lisa A. Palmer, George E. Sale, John I
Volume 25, Issue 9, Pages (September 2017)
Volume 132, Issue 1, Pages (January 2007)
Volume 19, Issue 5, Pages (November 2003)
Acquisition of a Functional T Cell Receptor during T Lymphocyte Development Is Enforced by HEB and E2A Transcription Factors  Mary Elizabeth Jones, Yuan.
Volume 10, Issue 5, Pages (November 2004)
Volume 19, Issue 7, Pages (May 2017)
Volume 25, Issue 8, Pages (August 2017)
Control of HIV Infection In Vivo Using Gene Therapy with a Secreted Entry Inhibitor  Alexander Falkenhagen, Jastaranpreet Singh, Sabah Asad, Danila Leontyev,
Tamar Hermesh, Bruno Moltedo, Thomas M. Moran, Carolina B. López 
Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.
Volume 29, Issue 1, Pages (July 2008)
In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.
Volume 43, Issue 2, Pages (August 2015)
Dynamics of Blood-Borne CD8 Memory T Cell Migration In Vivo
Ravindra Majeti, Christopher Y. Park, Irving L. Weissman 
Volume 19, Issue 2, Pages (February 2011)
Volume 10, Issue 6, Pages (December 2004)
Volume 38, Issue 1, Pages (January 2013)
Volume 13, Issue 2, Pages (February 2006)
Molecular Therapy - Oncolytics
Blimp-1 Transcription Factor Is Required for the Differentiation of Effector CD8+ T Cells and Memory Responses  Axel Kallies, Annie Xin, Gabrielle T.
Homeostasis of dendritic cells in lymphoid organs is controlled by regulation of their precursors via a feedback loop by Kristin Hochweller, Tewfik Miloud,
Kevin G. Haworth, Christina Ironside, Zachary K. Norgaard, Willimark M
Volume 32, Issue 5, Pages (May 2010)
An Interleukin-21- Interleukin-10-STAT3 Pathway Is Critical for Functional Maturation of Memory CD8+ T Cells  Weiguo Cui, Ying Liu, Jason S. Weinstein,
Volume 36, Issue 1, Pages (January 2012)
Volume 17, Issue 2, Pages (February 2009)
Myung H. Kim, Elizabeth J. Taparowsky, Chang H. Kim  Immunity 
Volume 21, Issue 5, Pages (May 2013)
Volume 126, Issue 6, Pages (September 2006)
Karima R.R. Siddiqui, Sophie Laffont, Fiona Powrie  Immunity 
Volume 34, Issue 5, Pages (May 2011)
Sibylle von Vietinghoff, Hui Ouyang, Klaus Ley  Kidney International 
David Voehringer, Kanade Shinkai, Richard M Locksley  Immunity 
Volume 38, Issue 6, Pages (June 2013)
Volume 35, Issue 4, Pages (October 2011)
Volume 13, Issue 6, Pages (November 2015)
Volume 25, Issue 4, Pages (April 2017)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Volume 23, Issue 4, Pages (October 2005)
Presentation transcript:

Molecular Therapy - Nucleic Acids RNAi-Mediated CCR5 Knockdown Provides HIV-1 Resistance to Memory T Cells in Humanized BLT Mice  Saki Shimizu, Gene-Errol Ringpis, Matthew D Marsden, Ruth V Cortado, Holly M Wilhalme, David Elashoff, Jerome A Zack, Irvin S Y Chen, Dong Sung An  Molecular Therapy - Nucleic Acids  Volume 4, (January 2015) DOI: 10.1038/mtna.2015.3 Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 CCR5 downregulation in EGFP+ CD4+ T cells in the reconstituted hu BLT mice. (a) Representative data for CCR5 expression in CD4+ T cells. Upper panel shows EGFP+ sh1005 vector marked CD4+ T cells and lower panel shows mCherry+ control vector marked CD4+ T cells. Numbers in each quadrant indicate the percentage. (b) The level of CCR5 expression was compared in EGFP+ and mCherry+ human CD4+ T cells in lymphoid tissues from multiple transplanted hu BLT mice. We normalized CCR5 expression level using the mean CCR5 expression in mCherry+ cells from peripheral blood (Blood) as 1. Samples were obtained between 21 and 26 weeks after human Thy/Liv implantation. Bar represents mean value; n indicates number of mice. Molecular Therapy - Nucleic Acids 2015 4, DOI: (10.1038/mtna.2015.3) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 2 Selective advantage of sh1005-modified CD4+ T cells in peripheral blood following R5 tropic HIV-1 challenge. Hu BLT mice were challenged with R5-tropic HIV-1NFNSX (top panel), X4-tropic HIV-1NL4-3 (middle panel) or mock (bottom panel) in 3 independent cohort of experiments (Ex1, EX2 and EX3). Relative change in CD4/CD8 ratio kinetics in EGFP+ (solid circle and solid line) and in mCherry+ (open circle and dashed line) human CD3+ T lymphocytes in peripheral blood were compared between −2 and 11 weeks after HIV-1 challenge. Error bar shows standard deviation. n, number of mice. Molecular Therapy - Nucleic Acids 2015 4, DOI: (10.1038/mtna.2015.3) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 3 Model slopes of CD4/CD8 ratio in peripheral blood. The relative changes in CD4/CD8 ratio of sh1005- (EGFP+) and no-shRNA control- (mCherry+) modified CD4+ T lymphocytes in peripheral blood were compared using a linear mixed effects model by including all data from the three cohort experiments (Ex1, EX2 and EX3). CD4/CD8 ratio in shRNA-transduced cells (EGFP+, dotted line) and control cells (mCherry, solid line) overlayed on raw values (EGFP+, open circle; mCherry+, solid circle) were shown. Molecular Therapy - Nucleic Acids 2015 4, DOI: (10.1038/mtna.2015.3) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 4 Maintenance of CD4/CD8 ratio in sh1005-modified CD4+ T cells in lymphoid tissue. (a) Representative data for percentage of CD4 and CD8 expression in EGFP+ (top panels) and mCherry+ (bottom panels) CD3+ T lymphocytes in bone marrow (BM), spleen, lung, small and large intestine (SI and LI) and intraepithelial lymphocytes (IEL) and lamina propria lymphocytes (LPL) in a R5 tropic HIV-1NFNSX–challenged hu BLT mice. CD4+ and CD8+ populations were gated and percentages are shown. (b) The data of CD4/CD8 ratio in EGFP+ CD3+ T lymphocytes (solid circle) and in mCherry+ lymphocytes (open circle) from all analyzed mice are shown. Samples were obtained between 8 and 12 weeks after HIV-1 challenge. A bar represents the mean value. **P ≤ 0.01. ***P ≤ 0.001. ****P ≤ 0.0001. Molecular Therapy - Nucleic Acids 2015 4, DOI: (10.1038/mtna.2015.3) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 5 Protection of CCR5 downregulated CD4+ memory T lymphocytes from R5-tropic HIV-1. (a) Percentage of central memory (CD45RA-/CD27+) in EGFP+ (Top panel) or mCherry+ (Bottom panel) CD4+ T lymphocytes in bone marrow (BM), spleen, lung, small and large intestine (SI and LI) lamina propria lymphocytes (LPL) and intraepithelial lymphocytes (IEL) from a R5 tropic HIV-1 infected hu BLT mouse. TCM indicates central memory T cells; TEM, effector memory T cells; and TTD, terminally differentiated cells. (b) Comparison of the level of % memory CD4+ T lymphocytes in EGFP+ (solid circle) and mCherry+ (open circle) from all analyzed mice (HIV-1NFNSX infected mice; n = 4, HIV-1NL4-3 infected mice; n = 4, mock infected mice; n = 3). A bar represents the mean value. ***P ≤ 0.001. ****P ≤ 0.0001. Molecular Therapy - Nucleic Acids 2015 4, DOI: (10.1038/mtna.2015.3) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 6 Maintenance of CD4/CD8 ratio in sh1005 modified memory T cells in lymphoid tissues. (a) Representative data showing percentage of CD4 and CD8 expression in EGFP+ (top panels) and mCherry+ (bottom panels) memory T lymphocytes in bone marrow (BM), spleen, lung, small and large intestine (SI and LI) lamina propria lymphocytes (LPL) and intraepithelial lymphocytes (IEL) in a R5 tropic HIV-1NFNSX–challenged hu BLT mice. CD4+ and CD8+ populations were gated and percentages are shown. (b) CD4/CD8 ratios in EGFP+ memory T lymphocytes (solid circle) and in mCherry+ lymphocytes (open circle) from all analyzed mice are shown. A bar represents the mean value. **P ≤ 0.01. ***P ≤ 0.001. ****P ≤ 0.0001. Molecular Therapy - Nucleic Acids 2015 4, DOI: (10.1038/mtna.2015.3) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions

Figure 7 Protection of sh1005-modified splenocytes. Comparison of p24 reactivation in sh1005 (EGFP+) and no shRNA (mCherry+) population ex vivo. Splenocytes were isolated from R5-tropic HIV-1NFNSX–challenged hu BLT mice (n = 7) or X4-tropic HIV-1NL4-3–challenged hu BLT mice (n = 7). Splenocytes were isolated, stimulated with PHA/IL-2 for 5 days to reactivate HIV-1 and stained with anti-HIV-1 p24 gag monoclonal antibodies. (a) Representative p24 intracellular staining data in CD45+CD3+CD8- cell population were shown. (b) Results of p24 reactivation in EGFP+ population (solid circle) and in mCherry+ population (open circle) from all analyzed mice are shown. The percentages of p24 expression within EGFP+ or mCherry+ populations were normalized based on % each marker (EGFP or mCherry) expression for the comparison. *P ≤ 0.05. n.s., not significant. Molecular Therapy - Nucleic Acids 2015 4, DOI: (10.1038/mtna.2015.3) Copyright © 2015 American Society of Gene & Cell Therapy Terms and Conditions